Board of directors
Chief Executive Officer
Enrico Bastianelli is the founder of TheraVet. Medical Doctor by training and holder of an MBA, Enrico Bastianelli acquired his business experience at McKinsey & Co. After creating several biotech companies, he founded and led Bone Therapeutics (a human bone cell therapy company) for 10 years. During this period, he took up many challenges such as the company's IPO (2015). He has 20 years of experience in biotech and medtech management.
Dr Simon Wheeler, BVSc, PhD, DECVN, MBA, FRCVS, is an expert in animal health and veterinary medicine. He has more than 20 years’ experience working for major pharmaceutical groups in which he has held numerous executive roles, and has worked for more than 20 years in academia. Dr Wheeler has a PhD in Veterinary Medicine from the Royal Veterinary College and an MBA from the Open University Business School. He is Managing Director of Veterinary Neurology Ltd, and he previously spent 10 years at Novartis Animal Health, including a four-year period with Novartis Venture Fund. Dr Wheeler has previously served as Chairman of the Academic Board of the European School of Veterinary Postgraduate Studies and is a director of Anifera Ltd, a start-up in the antimicrobial resistance arena. He consults on veterinary neurology clinical patients.
Jean-Philippe Mathieu is investment manager at INVESTSUD Group. After a PhD in materials science at the University of Liège and a master's degree in management at HEC Liège, he held various positions in the banking sector for more than 10 years. With his scientific background and expertise in Corporate finance, he has joined the venture capital group, Investsud, 5 years ago. Since then, he has accompanied many companies in start-up phase within different sectors : digital, IoT, Medtech...
Dr Nesya Goris, PhD, is co-founder and Chief Development Officer at ViroVet. She has a Master in Science from the University of Leuven and a PhD in Veterinary Sciences from the University of Ghent. After starting her career at Belgium’s reference laboratory for animal diseases, she became Chief Scientist at Okapi Sciences for six years before it was taken over by Aratana Therapeutics, where she was appointed VP Discovery Research and contributed to the commercial launch of Galliprant, a treatment for canine osteoarthritis. Currently, Dr Goris combines her role at ViroVet with that of Technical and Regulatory Director at Animab BV. She is also a member of the Board of Directors of Flanders Vaccine, an editor for the academic journal Antiviral Research and a lecturer at the University of Leuven in Belgium.
Julie Winand holds a PhD in Biochemistry and Cellular Biology carried out at the Catholic University of Louvain (Belgium). Before joining TheraVet, Julie worked at Bone Therapeutics and Novasep where she acquired experience in Product and Business Development.
Dr Christian Schirvel DVM., MSc, is hugely experienced in the field of animal health, having spent more than 30 years working for pharmaceutical groups such as Mérieux, Merial, Vétoquinol, Novartis and Elanco. Before joining TheraVet’s board, he was Head of Business Development and Licensing (EMEA and APAC) at Elanco. He also spent almost seven years at Swiss pharmaceutical group Novartis Animal Health as Head of Business Development and Licensing for parasiticides and therapeutic products. Previously in his career, Christian spent nine years at Rhône Mérieux, holding several key roles including Head of Strategic Development. He also is an independent Consultant (Vel-Vet AH Consulting) for small and mid-size Animal Health Companies, supporting them defining their strategy in general. He has a degree from the University of Liège in Belgium.